Order byBest matchMost fresh
23andMe was once worth $6 billion. What's left of the DNA testing startup is being bought for $256 million.
Regeneron is buying the assets of 23andMe, which filed for Chapter 11 bankruptcy in March after facing a series of hurdles including a data breach.
23andMe sells gene-testing business to DNA drug maker Regeneron
Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million people, to the drug developer Regeneron Pharmaceuticals for $256 million.
Struggling DNA testing firm 23andMe to be bought for $256m
The DNA testing firm 23andMe says it has entered into an agreement to be acquired by Regeneron Pharmaceuticals for $256m (£192m). It comes two months after the company filed for bankruptcy protection in the US.
Biotech company Regeneron buying 23andMe for $256 million
The proposed transaction with Regeneron includes 23andMe’s personal genome service and total health and research services.
Timeline: 23andMe’s Journey From DNA Testing Pioneer to Bankruptcy Sale
What happened to 23andMe? Here's a look at its history from launch to bankruptcy and acquisition by Regeneron.
Explore more
A drug developer is buying 23andMe - what does that mean for your DNA data?
The top bidder in the DNA testing firm's bankruptcy auction, Regeneron vows to prioritize the privacy, security, and ethical use of customer data.
Stock Movers: 23andMe, Reddit, Royal Caribbean
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.
Feedback